期刊文献+

胆固醇吸收抑制剂Ezetimibe合成工艺研究

Study on the Synthesis of Ezetimibe
下载PDF
导出
摘要 目的合成胆固醇吸收抑制剂Ezetimibe。方法以戊二酸酐和氟苯为始原料,经傅克反应、酯化、羰基还原、水解、内酯化得到(6S)-6-(4-氟苯基)四氢-2H-吡喃-2-酮,(6S)-6-(4-氟苯基)四氢-2H-吡喃-2-酮与4-苄氧基苯亚甲基-4-氟苯胺反应得到反1-(4-氟苯基)-3-[3(S)-(4-氟苯基-3-羟基丙基)-4-(4-苄氧基苯基)2-氮杂环丁酮,反1-(4-氟苯基)-3-[3(S)-(4-氟苯基-3-羟基丙基)-4-(4-苄氧基苯基)2-氮杂环丁酮再经脱苄、拆分后得到Ezetimibe。结果与结论目标化合物的结构经1H-NMR、MS谱等确证,总收率为18.6%。经改进,步骤中的酯化、还原、成环、脱苄步骤均得到有效优化,较大的降低了合成难度。 :OBJECTIVE To synthesize ezetimibe.METHODS Starting from dihydro-2H-pyran-2,6(3H)-dione and fluorobenzene,(S)-6-(4-fluorophenyl)tetrahydro-2H-pyran-2-one was obtained by Friedel-Crafts acylation,esterification,carbonyl reduction,hydrolysis and lactonization.The obtained pyran coupled with(E)-N-(4-(benzyloxy)benzylidene)-4-fluoroaniline to give 4-(4-(benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)azetidin-2-one.And then it was followed by debenzylation and resolution of the racemates to yield the target compound ezetimibe.RESULTS and CONCLUISON The overall yield of this method is 18.6%.The esterification,carbonyl reduction,annelation and debenzylation in the process were optimized well.
作者 涂豪慧 朱琦峰 杨金花 黄越燕 TU Hao-hui;ZHU Qi-feng;YANG Jin-hua;HUANG Yue-Yan(College of Medicine,Jiaxing University,Jiaxing 314001,China)
出处 《海峡药学》 2019年第2期65-67,共3页 Strait Pharmaceutical Journal
基金 浙江省大学生科技创新活动计划项目(2017R417039) 浙江省嘉兴市科技计划项目(2016AY23095)
关键词 胆固醇吸收抑制剂 EZETIMIBE 合成工艺 Hypocholesterolemic agent Ezetimibe Process improvement
  • 相关文献

参考文献3

二级参考文献21

  • 1Thiruvengadam TK,Fu XY,Tann CH,et al.Process for the synthesis of azetidinones and intermediates for use as hypocholesterolemics[P].WO:2000034240,2000-06-15.(CA 2000,133:17327)
  • 2Chiu JS,Colon C,Fu XY,et al.Process for the synthesis of azetidinones[P].US:6207822,2001-03-27.(CA 2001,134:252201)
  • 3Wu G,Wong Y,Chen X,et al.A novel one-step diastereo-and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors[J].J Org Chem,1999,64 (10):3714-3718.
  • 4GOTTO A M, SORBERA L A. Hypercholesterole mia: looking forward [ J ]. Clin Cardiol, 2003, 26 (Suppl, 1) :21 -28.
  • 5OHISHI K, AIYMA R, HATANO H, et al. Structure- activity relatiotaship of N-( 3, 5-dimethoxy-4-n-oc- tyloxycimnamoyl) -N'- ( 3,4-dimethylphenyl ) pipera- zine and analogues as inhibitors of acyl-CoA:choles- terol-acyltransferase[ J ]. Chem Pharm Bull, 2011,49 (47) : 830 - 839.
  • 6GAGNE C, GAUDET D, BRUCKERT E, et al. Effi- cacy and safety of ezetimibe coadministered with ator- vastatin or simvastatin inpatients with homozygous fa- milial hypercholesterolemia [ J ]. Circulation, 2002, 105 (21) :2469 - 2475.
  • 7WAYNE D V, ROSY S, HARRY R D, et al. 2-Aze- tidinone cholesterol absorption inhibitors: increased potency by substitution of the C-4 phenyl ring [ J ]. Bioorg Med Chem, 1998,6 (9) : 1429 - 1437.
  • 8WU G Z, WONG Y S, CHEN X, et al. A novel one- step diastereo and enantioselective formation of trans- azetidinones and its application to the total synthesis of cholesterol absorption inhibitors [ J ] J Org Chem, 1999,64(10) :3714 -3718.
  • 9SudhopT,LutjohannD,KodalA, et al.Inhibitor of intesti-nal cholesterol absorption by ezetimibe in humans[].Circulation.2002
  • 10WuGZ,ChenX,WongYS, et al.3-hydroxyγ-lactone basedenantioselective synthesis of azetidinones[].WO:.1998

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部